BAY63-2521
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for BAY63-2521, covering 2014-02-26 to 2025-07-28. Get the full timeline:
Most recent: Clinical Trial Update: Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH) [Phase 2]